Current Heart Failure Reports最新文献_第3页

Insights and Opportunities from Multimarker Evaluation of Heart Failure: Lessons from BIOSTAT-HF. 来自心力衰竭多标志物评估的见解和机遇：来自BIOSTAT-HF的经验教训。

IF 3.8

Current Heart Failure Reports Pub Date : 2025-01-29 DOI: 10.1007/s11897-024-00694-6

Antoinette S Birs, Donya Mazdeyasnan, Lori B Daniels

{"title":"Insights and Opportunities from Multimarker Evaluation of Heart Failure: Lessons from BIOSTAT-HF.","authors":"Antoinette S Birs, Donya Mazdeyasnan, Lori B Daniels","doi":"10.1007/s11897-024-00694-6","DOIUrl":"10.1007/s11897-024-00694-6","url":null,"abstract":"Purpose of review: Heart failure is a complex and heterogenous disease state that affects millions worldwide. Over recent decades, advancements in medical therapy and device implementation have significantly transformed the landscape of heart failure outcomes, while improvements in imaging modalities and greater accessibility to genome sequencing have led to increasing recognition of distinct heart failure endotypes. There is rising evidence to suggest all patients do not benefit equally from intensification of guideline directed medical therapy (GDMT). Efforts to personalize medical therapy to maximize benefits while minimizing side effects remains an ongoing challenge. We review key manuscripts from The BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF), a multicenter observational study conducted across Europe, which prospectively enrolled patients with acute or worsening heart failure.Findings: BIOSTAT-CHF was designed to characterize biological pathways associated with varied patient responses to GDMT for heart failure. Utilizing a diverse cohort of European patients, the authors were able to develop risk models to predict mortality and heart failure hospitalization from clinically available data plus standard and novel biomarkers. They also utilized modeling to refine characterization of heart failure subtypes and personalization of GDMT titration. In this review we highlight key insights from the BIOSTAT-CHF cohort and how they relate to: (1) prognosis and monitoring treatment response in heart failure, (2) personalization of heart failure treatment, and (3) elucidation of biological pathways and future directions for research. These insights summarize how BIOSTAT-CHF has contributed to a deeper understanding of heart failure, focusing on using biomarkers personalizing treatment approaches, with a goal of ultimately improving patient outcomes.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"22 1","pages":"7"},"PeriodicalIF":3.8,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Disease Network-Based Approaches to Study Comorbidity in Heart Failure: Current State and Future Perspectives. 基于疾病网络的方法研究心力衰竭共病：现状和未来展望。

IF 3.8

Current Heart Failure Reports Pub Date : 2024-12-27 DOI: 10.1007/s11897-024-00693-7

Sergio Alejandro Gomez-Ochoa, Jan D Lanzer, Rebecca T Levinson

{"title":"Disease Network-Based Approaches to Study Comorbidity in Heart Failure: Current State and Future Perspectives.","authors":"Sergio Alejandro Gomez-Ochoa, Jan D Lanzer, Rebecca T Levinson","doi":"10.1007/s11897-024-00693-7","DOIUrl":"10.1007/s11897-024-00693-7","url":null,"abstract":"Purpose of review: Heart failure (HF) is often accompanied by a constellation of comorbidities, leading to diverse patient presentations and clinical trajectories. While traditional methods have provided valuable insights into our understanding of HF, network medicine approaches seek to leverage these complex relationships by analyzing disease at a systems level. This review introduces the concepts of network medicine and explores the use of comorbidity networks to study HF and heart disease.Recent findings: Comorbidity networks are used to understand disease trajectories, predict outcomes, and uncover potential molecular mechanisms through identification of genes and pathways relevant to comorbidity. These networks have shown the importance of non-cardiovascular comorbidities to the clinical journey of patients with HF. However, the community should be aware of important limitations in developing and implementing these methods. Network approaches hold promise for unraveling the impact of comorbidities in the complex presentation and genetics of HF. Methods that consider comorbidity presence and timing have the potential to help optimize management strategies and identify pathophysiological mechanisms.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"22 1","pages":"6"},"PeriodicalIF":3.8,"publicationDate":"2024-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11671564/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142892255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial Intelligence Advancements in Cardiomyopathies: Implications for Diagnosis and Management of Arrhythmogenic Cardiomyopathy. 人工智能在心肌病中的进展：对心律失常性心肌病的诊断和治疗的意义。

IF 3.8

Current Heart Failure Reports Pub Date : 2024-12-11 DOI: 10.1007/s11897-024-00688-4

Arman Salavati, C Nina van der Wilt, Martina Calore, René van Es, Alessandra Rampazzo, Pim van der Harst, Frank G van Steenbeek, J Peter van Tintelen, Magdalena Harakalova, Anneline S J M Te Riele

{"title":"Artificial Intelligence Advancements in Cardiomyopathies: Implications for Diagnosis and Management of Arrhythmogenic Cardiomyopathy.","authors":"Arman Salavati, C Nina van der Wilt, Martina Calore, René van Es, Alessandra Rampazzo, Pim van der Harst, Frank G van Steenbeek, J Peter van Tintelen, Magdalena Harakalova, Anneline S J M Te Riele","doi":"10.1007/s11897-024-00688-4","DOIUrl":"10.1007/s11897-024-00688-4","url":null,"abstract":"Purpose of review: This review aims to explore the emerging potential of artificial intelligence (AI) in refining risk prediction, clinical diagnosis, and treatment stratification for cardiomyopathies, with a specific emphasis on arrhythmogenic cardiomyopathy (ACM).Recent findings: Recent developments highlight the capacity of AI to construct sophisticated models that accurately distinguish affected from non-affected cardiomyopathy patients. These AI-driven approaches not only offer precision in risk prediction and diagnostics but also enable early identification of individuals at high risk of developing cardiomyopathy, even before symptoms occur. These models have the potential to utilise diverse clinical input datasets such as electrocardiogram recordings, cardiac imaging, and other multi-modal genetic and omics datasets. Despite their current underrepresentation in literature, ACM diagnosis and risk prediction are expected to greatly benefit from AI computational capabilities, as has been the case for other cardiomyopathies. As AI-based models improve, larger and more complicated datasets can be combined. These more complex integrated datasets with larger sample sizes will contribute to further pathophysiological insights, better disease recognition, risk prediction, and improved patient outcomes.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"22 1","pages":"5"},"PeriodicalIF":3.8,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142806373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gamification and its Potential for Better Engagement in the Management of Heart Failure or Quality of Care Registries: A Viewpoint. 游戏化及其在心力衰竭或护理质量登记管理中更好参与的潜力：一个观点。

IF 3.8

Current Heart Failure Reports Pub Date : 2024-12-05 DOI: 10.1007/s11897-024-00692-8

Abdul Shakoor, Chanu Mohansingh, Robert M A van der Boon, Jasper J Brugts, Jeroen Schaap

{"title":"Gamification and its Potential for Better Engagement in the Management of Heart Failure or Quality of Care Registries: A Viewpoint.","authors":"Abdul Shakoor, Chanu Mohansingh, Robert M A van der Boon, Jasper J Brugts, Jeroen Schaap","doi":"10.1007/s11897-024-00692-8","DOIUrl":"10.1007/s11897-024-00692-8","url":null,"abstract":"Over the past decade, gamification, an umbrella term that refers to tools that engage and motivate participants through the use of game design elements (e.g., challenges and rewards) in a non-gaming context, has emerged as a promising approach in the management of chronic diseases. Specifically, it has been demonstrated to be effective in the education of both patients as well as healthcare professionals on medication adherence, risk reduction, patient self-care, and rehabilitation. There is some evidence suggesting that gamification might have similar benefits for heart failure (HF) patients and their health care professionals. This is of specific interest since HF is a chronic disease associated with a severely compromised long-term prognosis and subsequent high health care resource utilization. However, more robust research is needed to confirm these findings and determine the optimal method, as well as barriers, to the implementation of gamification in the working process of health care professionals or treatment adherence to patients specifically in the setting of HF. This viewpoint explores the literature concerning HF and gamification and aims to identify its various potentials in the management of HF patients.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"22 1","pages":"4"},"PeriodicalIF":3.8,"publicationDate":"2024-12-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142784281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biomarkers of Hemodynamic Congestion in Heart Failure. 心力衰竭血流动力学充盈的生物标志物

IF 3.8

Current Heart Failure Reports Pub Date : 2024-12-01 Epub Date: 2024-09-19 DOI: 10.1007/s11897-024-00684-8

Alison Brann, Sean Selko, Ethan Krauspe, Kevin Shah

{"title":"Biomarkers of Hemodynamic Congestion in Heart Failure.","authors":"Alison Brann, Sean Selko, Ethan Krauspe, Kevin Shah","doi":"10.1007/s11897-024-00684-8","DOIUrl":"10.1007/s11897-024-00684-8","url":null,"abstract":"Purpose of review: The purpose of this review is to describe the evidence behind various blood and imaging-based biomarkers that can improve the identification of congestion when not clearly evident on routine examination.Recent findings: The natriuretic peptides (NPs) BNP and NT-proBNP have been shown to closely correlate with intra-cardiac filling pressures, both at baseline and when trended following improvement in congestion. Additionally, NPs rise well before clinical congestion is apparent so can be used as a tool to help identify subclinical HF decompensation. Additional serum-based biomarkers including MR-proANP and CA-125 can be helpful in assisting with diagnostic certainty when BNP or NT-proBNP are in the \"grey zone\" or when factors are present which may confound NP levels. Additionally, the emerging use of ultrasound techniques may enhance our ability to fine-tune the assessment and treatment of congestion. Biomarkers, including the blood-based natriuretic peptides and markers on bedside point of care ultrasound, can be used as non-invasive indices of hemodynamic congestion. These biomarkers are particularly valuable to incorporate when the degree of a patient's congestion is not apparent on clinical exam, and they can provide important prognostic information and help guide clinical management.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"541-553"},"PeriodicalIF":3.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Revisiting Biomarkers of Cardiac Allograft Vasculopathy: Addressing the Achilles Heel of Heart Transplantation. 重新审视心脏移植血管病变的生物标志物：解决心脏移植的致命弱点。

IF 3.8

Current Heart Failure Reports Pub Date : 2024-12-01 Epub Date: 2024-10-17 DOI: 10.1007/s11897-024-00685-7

Patrick E O'Hara, Ananya Gorrai, Maryjane Farr, Matthias Peltz, Hadi Beaini, Yasbanoo Moayedi, Sharon Chih, Lauren K Truby

{"title":"Revisiting Biomarkers of Cardiac Allograft Vasculopathy: Addressing the Achilles Heel of Heart Transplantation.","authors":"Patrick E O'Hara, Ananya Gorrai, Maryjane Farr, Matthias Peltz, Hadi Beaini, Yasbanoo Moayedi, Sharon Chih, Lauren K Truby","doi":"10.1007/s11897-024-00685-7","DOIUrl":"10.1007/s11897-024-00685-7","url":null,"abstract":"Nearly half of heart transplant recipients will be diagnosed with cardiac allograft vasculopathy (CAV) within five years after transplantation. Advanced CAV can lead to worsening heart failure as well as arrhythmias and sudden cardiac death. The only curative therapy for end-stage CAV is re-transplantation. Current diagnostic methods are invasive and limited by poor sensitivity in early disease. Despite its high prevalence in the post-transplantpopulation, the underlying pathophysiology of this condition has yet to be fully described. It is thought to be primarily related to endothelial dysfunction, immune activation, and cardiometabolic disease. Biomarkers reflecting these underlying processes, particularly endothelial injury and immune activation, have shown early promise in discriminating prevalent CAV. Next-generation sequencing technologies such as proteomic and transcriptomic profiling have also provided further insight into the pathophysiology of CAV through the identification of novel biomarkers. Ultimately, these biomarkers may have a role in not only diagnosing CAV but also highlighting potential targets for disease-specific therapies. In this article, we review the current data for biomarkers in CAV and discuss future directions for biomarker identification..","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"580-590"},"PeriodicalIF":3.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Screening for Heart Failure: Biomarkers to Detect Heightened Risk in the General Population. 心力衰竭筛查：检测普通人群高风险的生物标志物。

IF 3.8

Current Heart Failure Reports Pub Date : 2024-12-01 Epub Date: 2024-09-17 DOI: 10.1007/s11897-024-00686-6

Leah B Kosyakovsky, Rudolf A de Boer, Jennifer E Ho

{"title":"Screening for Heart Failure: Biomarkers to Detect Heightened Risk in the General Population.","authors":"Leah B Kosyakovsky, Rudolf A de Boer, Jennifer E Ho","doi":"10.1007/s11897-024-00686-6","DOIUrl":"10.1007/s11897-024-00686-6","url":null,"abstract":"Purpose of review: Heart failure (HF) represents a growing global burden of morbidity and mortality. Identifying individuals at risk for HF development is increasingly important, particularly given the advent of disease-modifying therapies for HF as well as its major risk factors such as obesity actalnd diabetes. We aim to review the key circulating biomarkers associated with future HF which may contribute to HF risk prediction.Recent findings: While current guidelines recommend the use of natriuretic peptides and cardiac troponins in HF risk stratification, there are a diverse array of other emerging protein, metabolic, transcriptomic, and genomic biomarkers of future HF development. These biomarkers not only lend insight into the underlying pathophysiology of HF, which spans inflammation to cardiac fibrosis, but also offer an opportunity to further refine HF risk in addition to established biomarkers. As evolving techniques in molecular biology enable an increased understanding of the complex biologic contributions to HF pathophysiology, there is an important opportunity to construct integrated clinical and multi-omic models to best capture HF risk. Moving forward, future studies should seek to understand the contributions of sex differences, underlying comorbidity burden, and HF subtypes to an individual's HF risk. Further studies are necessary to fully define the clinical utility of biomarker screening approaches to refine HF risk assessment, as well as to link risk assessment directly to preventive strategies for HF.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"591-603"},"PeriodicalIF":3.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiogenic Shock: Focus on Non-Cardiac Biomarkers. 心源性休克：关注非心脏生物标志物。

IF 3.8

Current Heart Failure Reports Pub Date : 2024-12-01 Epub Date: 2024-07-30 DOI: 10.1007/s11897-024-00676-8

Hadi Beaini, Zainali Chunawala, Daniel Cheeran, Faris Araj, Christopher Wrobel, Lauren Truby, Amit Saha, Jennifer T Thibodeau, Maryjane Farr

引用次数: 0

Genetic Biomarkers in Heart Failure: From Gene Panels to Polygenic Risk Scores. 心力衰竭的遗传生物标志物：从基因面板到多基因风险评分。

IF 3.8

Current Heart Failure Reports Pub Date : 2024-12-01 Epub Date: 2024-10-15 DOI: 10.1007/s11897-024-00687-5

Marta Figueiral, Alessia Paldino, Luca Fazzini, Naveen L Pereira

{"title":"Genetic Biomarkers in Heart Failure: From Gene Panels to Polygenic Risk Scores.","authors":"Marta Figueiral, Alessia Paldino, Luca Fazzini, Naveen L Pereira","doi":"10.1007/s11897-024-00687-5","DOIUrl":"10.1007/s11897-024-00687-5","url":null,"abstract":"Purpose of review: This review aims to provide a comprehensive overview of the current understanding of genetic markers associated with heart failure (HF) and its underlying causative diseases, such as cardiomyopathies. It highlights the relevance of genetic biomarkers in diagnosing HF, predicting prognosis, potentially identifying its preclinical stages and identifying targets to enable the implementation of individualized medicine approaches.Recent findings: The prevalence of HF is increasing due to an aging population but with greater access to disease-modifying therapies. Advanced diagnostic tools such as cardiac magnetic resonance, nuclear imaging, and AI-enabled diagnostic testing are now being utilized to further characterize HF patients. Additionally, the importance of genetic testing in HF diagnosis and management is increasingly being recognized. Genetic biomarkers, including single nucleotide polymorphisms (SNPs) and rare genetic variants, are emerging as crucial tools for diagnosing HF substrates, determining prognosis and increasingly directing therapy. These genetic insights are key to optimizing HF management and delivering personalized treatment tailored to individual patients. HF is a complex syndrome affecting millions globally, characterized by high mortality and significant economic burden. Understanding the underlying etiologies of HF is essential for improving management and clinical outcomes. Recent advances highlight the use of multimodal assessments, including AI-enabled diagnostics and genetic testing, to better characterize and manage HF. Genetic biomarkers are particularly promising in identifying preclinical HF stages and providing personalized treatment options. The genetic contribution to HF is heterogeneous, with both monogenic and polygenic bases playing a role. These developments underscore the shift towards personalized medicine in HF management.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":" ","pages":"554-569"},"PeriodicalIF":3.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Troponin Elevation in Asymptomatic Cancer Patients: Unveiling Connections and Clinical Implications. 无症状癌症患者肌钙蛋白升高：揭示联系与临床意义

IF 3.8

Current Heart Failure Reports Pub Date : 2024-12-01 Epub Date: 2024-09-10 DOI: 10.1007/s11897-024-00681-x

Sebastian W Romann, Evangelos Giannitsis, Norbert Frey, Lorenz H Lehmann

引用次数: 0